Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Enzalutamide (Primary) ; Exemestane
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms ARB
- Sponsors Astellas Pharma Europe Ltd
- 29 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 29 Aug 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated